Coccidioidomycosis

Nathan W Stockamp; George R Thompson 3rd

doi:10.1016/j.idc.2015.10.008

Coccidioidomycosis

Infect Dis Clin North Am. 2016 Mar;30(1):229-46. doi: 10.1016/j.idc.2015.10.008. Epub 2015 Dec 29.

Authors

Nathan W Stockamp¹, George R Thompson 3rd²

Affiliations

¹ Division of Infectious Disease, Department of Internal Medicine, University of California, San Francisco, Fresno, San Francisco, CA, USA.
² Division of Infectious Diseases, Department of Internal Medicine, University of California, Davis, Davis, CA, USA; Department of Medical Microbiology and Immunology, University of California, Davis, Davis, CA, USA. Electronic address: grthompson@ucdavis.edu.

PMID: 26739609
DOI: 10.1016/j.idc.2015.10.008

Abstract

Coccidioides immitis and C posadasii are pathogenic dimorphic fungi responsible for causing coccidioidomycosis in the Southwestern United States and Central and South America. Antifungal therapy is beneficial and entails careful periodic assessment with therapies ranging from none or short courses of therapy to prolonged antifungal therapy. Factors that influence the decision to treat are the duration or severity of infection, radiographic findings, anticomplementary titers, presence of underlying immunosuppression, and comorbidities. Cure for disseminated infection is infrequent with current treatment regimens. This review summarizes the management guidelines for various disease manifestations and reviews data on challenging cases with newer agents.

Keywords: Coccidioides; Coccidioidomycosis; Epidemiology; Meningitis; Primary infection; Treatment.

Publication types

Review

MeSH terms

Antifungal Agents / therapeutic use*
Coccidioides
Coccidioidomycosis / diagnosis*
Coccidioidomycosis / drug therapy*
Coccidioidomycosis / epidemiology
Coccidioidomycosis / microbiology
Humans

Substances

Antifungal Agents